FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308402602> ?p ?o ?g. }

• W4308402602 abstract "<h3>Background</h3> While immunotherapy has improved outcomes for patients with metastatic non-small cell lung cancer (NSCLC) and melanoma, most progress despite standard treatment. Therefore, treatments with the potential to enhance the efficacy of existing immunotherapy-based regimens are being actively examined to further improve outcomes in these diseases. CD40 is a tumor necrosis factor receptor expressed on multiple immune cell populations as well as on tumor cells. CD40 activation drives B- and T-cell activation to evoke tumor-specific cytotoxic T-cell responses. SEA-CD40 is an investigational, receptor-agonistic, nonfucosylated, humanized IgG1 monoclonal antibody (mAb) directed to CD40. SEA-CD40 binds with high affinity to FcγRIIIa and CD40, resulting in enhanced effector function and CD40 agonism, allowing amplification of immune stimulation and antitumor activity. Preclinical studies have shown that SEA-CD40 combined with chemotherapy and pembrolizumab resulted in significant antitumor activity. This combination regimen has also demonstrated a tolerable safety profile, encouraging antitumor activity, and evidence of persistent immune activation in an ongoing phase 1 study (SGNS40-001, NCT02376699). Given the preclinical and clinical data supporting SEA-CD40 combined with pembrolizumab and/or chemotherapy, further investigation into additional diseases is warranted. <h3>Methods</h3> SGNS40-002 (NCT04993677) is a phase 2, open-label, multicenter trial designed to assess the antitumor activity, safety, and tolerability of SEA-CD40 in combination with pembrolizumab and/or chemotherapy in adults (≥18 years) with NSCLC or melanoma. Five indication-specific cohorts will explore 2 different regimens: cohorts 1–3 will receive SEA-CD40 with pembrolizumab while cohorts 4 and 5 will receive SEA-CD40, pembrolizumab, carboplatin, and pemetrexed. Cohort 1 will enroll patients with relapsed or refractory metastatic melanoma (≤3 prior lines of therapy, including an anti–programmed death/ligand 1 (PD-1/PD-L1) mAb within 90 days), cohort 2 will enroll patients with metastatic uveal melanoma, and cohort 3 will enroll patients with metastatic PD-1/PD-L1–naïve melanoma. Patients in cohorts 2 and 3 must have no prior therapy for advanced disease except adjuvant/neoadjuvant therapy. Cohorts 4 and 5 will include patients with NSCLC with a PD-L1 tumor proportion score of 1–49% or <1%, respectively. The primary endpoint is investigator-assessed confirmed objective response rate per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1). Secondary endpoints include incidence of adverse events; laboratory abnormalities; treatment interruptions, reductions or discontinuations; disease control rate; duration of response; progression-free survival; and overall survival. Exploratory endpoints include pharmacokinetic parameters, antidrug antibodies, biomarkers of response, and patient-reported quality of life. Enrollment is ongoing in North America and Europe. <h3>Trial Registration</h3> NCT04993677 <h3>Ethics Approval</h3> Institutional review boards or independent ethics committees of participating sites approved the trial, which will be conducted in compliance with the Declaration of Helsinki and International Conference on Harmonization Guidelines for Good Clinical Practice. All patients will provide written informed consent. <h3>Consent</h3> All patients will provide written informed consent." @default.
• W4308402602 created "2022-11-11" @default.
• W4308402602 creator A5002575629 @default.
• W4308402602 creator A5003177689 @default.
• W4308402602 creator A5003887338 @default.
• W4308402602 creator A5008917232 @default.
• W4308402602 creator A5014527725 @default.
• W4308402602 creator A5018322482 @default.
• W4308402602 creator A5021064276 @default.
• W4308402602 creator A5028592995 @default.
• W4308402602 creator A5035218748 @default.
• W4308402602 creator A5038596323 @default.
• W4308402602 creator A5047981602 @default.
• W4308402602 creator A5090769354 @default.
• W4308402602 date "2022-11-01" @default.
• W4308402602 modified "2023-09-30" @default.
• W4308402602 title "705 Phase 2 study of SEA-CD40 combination therapies in advanced malignancies (SGNS40–002, trial in progress)" @default.
• W4308402602 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0705" @default.
• W4308402602 hasPublicationYear "2022" @default.
• W4308402602 type Work @default.
• W4308402602 citedByCount "0" @default.
• W4308402602 crossrefType "proceedings-article" @default.
• W4308402602 hasAuthorship W4308402602A5002575629 @default.
• W4308402602 hasAuthorship W4308402602A5003177689 @default.
• W4308402602 hasAuthorship W4308402602A5003887338 @default.
• W4308402602 hasAuthorship W4308402602A5008917232 @default.
• W4308402602 hasAuthorship W4308402602A5014527725 @default.
• W4308402602 hasAuthorship W4308402602A5018322482 @default.
• W4308402602 hasAuthorship W4308402602A5021064276 @default.
• W4308402602 hasAuthorship W4308402602A5028592995 @default.
• W4308402602 hasAuthorship W4308402602A5035218748 @default.
• W4308402602 hasAuthorship W4308402602A5038596323 @default.
• W4308402602 hasAuthorship W4308402602A5047981602 @default.
• W4308402602 hasAuthorship W4308402602A5090769354 @default.
• W4308402602 hasBestOaLocation W43084026021 @default.
• W4308402602 hasConcept C121608353 @default.
• W4308402602 hasConcept C126322002 @default.
• W4308402602 hasConcept C143998085 @default.
• W4308402602 hasConcept C154317977 @default.
• W4308402602 hasConcept C197934379 @default.
• W4308402602 hasConcept C202751555 @default.
• W4308402602 hasConcept C203014093 @default.
• W4308402602 hasConcept C2777701055 @default.
• W4308402602 hasConcept C2778375690 @default.
• W4308402602 hasConcept C2780057760 @default.
• W4308402602 hasConcept C39347974 @default.
• W4308402602 hasConcept C502942594 @default.
• W4308402602 hasConcept C55493867 @default.
• W4308402602 hasConcept C71924100 @default.
• W4308402602 hasConcept C86803240 @default.
• W4308402602 hasConceptScore W4308402602C121608353 @default.
• W4308402602 hasConceptScore W4308402602C126322002 @default.
• W4308402602 hasConceptScore W4308402602C143998085 @default.
• W4308402602 hasConceptScore W4308402602C154317977 @default.
• W4308402602 hasConceptScore W4308402602C197934379 @default.
• W4308402602 hasConceptScore W4308402602C202751555 @default.
• W4308402602 hasConceptScore W4308402602C203014093 @default.
• W4308402602 hasConceptScore W4308402602C2777701055 @default.
• W4308402602 hasConceptScore W4308402602C2778375690 @default.
• W4308402602 hasConceptScore W4308402602C2780057760 @default.
• W4308402602 hasConceptScore W4308402602C39347974 @default.
• W4308402602 hasConceptScore W4308402602C502942594 @default.
• W4308402602 hasConceptScore W4308402602C55493867 @default.
• W4308402602 hasConceptScore W4308402602C71924100 @default.
• W4308402602 hasConceptScore W4308402602C86803240 @default.
• W4308402602 hasLocation W43084026021 @default.
• W4308402602 hasOpenAccess W4308402602 @default.
• W4308402602 hasPrimaryLocation W43084026021 @default.
• W4308402602 hasRelatedWork W2342781363 @default.
• W4308402602 hasRelatedWork W2610751918 @default.
• W4308402602 hasRelatedWork W2777867648 @default.
• W4308402602 hasRelatedWork W2786497694 @default.
• W4308402602 hasRelatedWork W2904110710 @default.
• W4308402602 hasRelatedWork W2969782175 @default.
• W4308402602 hasRelatedWork W3153432702 @default.
• W4308402602 hasRelatedWork W3161613553 @default.
• W4308402602 hasRelatedWork W3215044659 @default.
• W4308402602 hasRelatedWork W4309809336 @default.
• W4308402602 isParatext "false" @default.
• W4308402602 isRetracted "false" @default.
• W4308402602 workType "article" @default.